Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New funding for research into enzootic pneumonia
The bacteria responsible for the disease is present in 80 per cent of UK herds.
Government awards funding to researchers developing vaccine.

Researchers at the Royal Veterinary College have been awarded funding to create a vaccine for enzootic pneumonia by the Department for Environment, Food and Rural Affairs and the Biotechnology and Biological Sciences Research Council (BBSRC).

Enzootic pneumonia is the most common respiratory disease in pigs, with Mycoplasma hyopneumoniae (M.hyop), the bacteria which causes the disease, present in 80 per cent of UK herds. It is predominantly transmitted to piglets through lactation from an infected pig and can result in a 16 per cent reduction in growth.

Currently, treatment relies on antibiotics, with M.hyop susceptible to several varieties. However, owing to the need to reduce the overall use of antibiotics in veterinary medicine to prevent drug-resistant strains of bacteria developing, scientists are keen to find an alternative.

The research team, which will include Professor Dirk Werling, Dr Rob Noad, and Dr Sonja Jeckel, will work on developing the first commercially available vaccine for enzootic pneumonia. The researchers will also study how to improve protocols to eliminate M.hyop from pig herds to further minimise the potential transmission of the disease.

Previous research, funded by the BBSRC and the Agriculture and Horticulture Development Board, identified the genes which allow the pathogen to survive in pigs.

Professor Werling said: “Infection of Mycoplasma hyopneumoniae is a really debilitating disease in pigs that causes huge economic losses for farmers. I am very pleased that we will be able to continue working with a pharmaceutical partner to develop a new vaccine using state-of the-art technologies.”


Image (C) Shutterstock

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.